Sanford C. Bernstein Reiterates “€115.00” Price Target for Merck KGaA (MRK)

Sanford C. Bernstein set a €115.00 ($133.72) price target on Merck KGaA (FRA:MRK) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the healthcare company’s stock.

Several other equities analysts have also recently commented on the stock. UBS AG set a €120.00 ($139.53) target price on shares of Merck KGaA and gave the company a buy rating in a research report on Monday, October 23rd. equinet AG set a €112.00 ($130.23) price objective on shares of Merck KGaA and gave the stock a buy rating in a research report on Thursday, August 31st. Societe Generale set a €103.00 ($119.77) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, September 5th. Goldman Sachs Group, Inc. (The) set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, September 6th. Finally, Independent Research GmbH set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Monday, August 28th. Eleven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Merck KGaA currently has an average rating of Buy and an average price target of €109.00 ($126.74).

Merck KGaA (MRK) opened at €90.56 ($105.30) on Wednesday. Merck KGaA has a 12-month low of €89.21 ($103.73) and a 12-month high of €115.00 ($133.72).

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/18/sanford-c-bernstein-reiterates-115-00-price-target-for-merck-kgaa-mrk.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply